Our findings provide convincing evidence for differential associations of individual n-6 PUFAs (i.e. LA, GLA, DGLA, DTA, and n6-DPA) with CHD or stroke risks, which may partly explain the conflicting results from RCTs of n-6 PUFA supplementation.3 Some evidence has suggested potential cardiometabolic benefits of dietary n-6 PUFA, including favourable associations with lipids, inflammation, insulin resistance, blood pressure, and body composition37–39. This evidence concerns the gene INS and coronary artery disorder.